Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials Jing LiHengxiu Yan Review Article 13 July 2018 Pages: 571 - 583
A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2) Yusuke TanakaYutaka UedaTadashi Kimura Original Article Open access 20 July 2018 Pages: 585 - 592
Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation Feng NiChang-you YanZhi-gang Zhang Original Article 21 July 2018 Pages: 593 - 605
Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer Weiwei HuangJian LiuLin Lin Original Article 24 July 2018 Pages: 607 - 613
Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects Hong ZhangQingmei LiYanhua Ding Original Article 24 July 2018 Pages: 615 - 623
The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer Kyoko YamaguchiHitoshi KusabaEishi Baba Original Article 24 July 2018 Pages: 625 - 633
Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1 Mukul R. JainJogeswar MohapatraRanjit C. Desai Original Article 25 July 2018 Pages: 635 - 647
Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer Haruhiko YamazakiTomoyuki YokoseMunetaka Masuda Original Article 26 July 2018 Pages: 649 - 654
Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial Wen ZhangChunxia DuAiping Zhou Original Article Open access 23 July 2018 Pages: 655 - 660
Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy Hitoshi ShibuyaSusumu HijiokaTakuji Okusaka Original Article 27 July 2018 Pages: 661 - 668
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models Emma C. MartinLeon AaronsJames W. T. Yates Original Article Open access 27 July 2018 Pages: 669 - 675
Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand–foot skin reactions in sorafenib-treated patients Kosuke SaitoMasafumi IkedaShunsuke Kondo Original Article 30 July 2018 Pages: 677 - 684
An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy Noboru YamamotoHirotsugu KenmotsuKazuhiko Nakagawa Original Article Open access 03 August 2018 Pages: 685 - 694
A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer Richard GreilSigrun Greil-ResslerPeter P. Sordillo Original Article Open access 03 August 2018 Pages: 695 - 706
Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer Junichi NishimuraJunichi HasegawaClinical Study Group of Osaka University (CSGO) Colorectal Group Original Article 04 August 2018 Pages: 707 - 716
Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients Kana AkiyamaTetsuo KumeTakashi Ikeda Original Article Open access 06 August 2018 Pages: 717 - 721
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors Stephen V. LiuSusan G. GroshenEdward M. Newman Clinical Trial Report 20 August 2018 Pages: 723 - 732
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071) Markus MoehlerArno Schadthe EORTC Gastrointestinal Tract Cancer Group Short Communication 13 August 2018 Pages: 733 - 739
